225 related articles for article (PubMed ID: 37528405)
21. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry.
Ding WY; Calvert P; Gupta D; Huisman MV; Lip GYH;
Clin Res Cardiol; 2022 Sep; 111(9):1057-1068. PubMed ID: 35488127
[TBL] [Abstract][Full Text] [Related]
22. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
Bayer V; Kotalczyk A; Kea B; Teutsch C; Larsen P; Button D; Huisman MV; Lip GYH; Olshansky B
J Am Heart Assoc; 2022 Mar; 11(6):e023907. PubMed ID: 35243870
[TBL] [Abstract][Full Text] [Related]
23. Utilization of Anticoagulants in Nonvalvular Atrial Fibrillation Before and After Catheter Ablation at Shanghai, China.
Tingting C; Yuzhu W; Lin Z; Ran L; Jing L; Yi W; Xiaoyu L; Qianzhou L
Clin Appl Thromb Hemost; 2019; 25():1076029619826260. PubMed ID: 30754983
[TBL] [Abstract][Full Text] [Related]
24. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
25. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry.
Lip GYH; Kotalczyk A; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Marler S; Gurusamy VK; Huisman MV;
Clin Res Cardiol; 2022 May; 111(5):560-573. PubMed ID: 35294625
[TBL] [Abstract][Full Text] [Related]
27. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
[TBL] [Abstract][Full Text] [Related]
28. Gender differences in antithrombotic treatment in patients with atrial fibrillation from Spain versus the rest of Western Europe. GLORIA-AF Program.
López-Sendón JL; Alonso-Rodríguez D; Barón-Esquivias G; Cosin-Sales J; Marín F; Galera-Llorca J; Jiménez N; Marler S; Huisman MV; Lip GYH;
Med Clin (Barc); 2022 Aug; 159(4):177-182. PubMed ID: 34895750
[TBL] [Abstract][Full Text] [Related]
29. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
[TBL] [Abstract][Full Text] [Related]
30. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
Benetou DR; Varlamos C; Ktenas D; Tsiafoutis I; Koutouzis M; Bampali T; Mantis C; Zarifis J; Skalidis E; Aravantinos D; Varvarousis D; Lianos I; Kanakakis J; Pisimisis E; Ziakas A; Davlouros P; Alexopoulos D;
Cardiovasc Drugs Ther; 2021 Feb; 35(1):11-20. PubMed ID: 33034806
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
[TBL] [Abstract][Full Text] [Related]
32. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.
Lee SR; Choi EK; Han KD; Cha MJ; Oh S; Lip GYH
PLoS One; 2017; 12(12):e0189495. PubMed ID: 29261716
[TBL] [Abstract][Full Text] [Related]
33. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.
Kozieł M; Mazurek M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Brandes A; Paquette M; Zint K; França LR; Lu S; Bartels DB; Huisman MV; Lip GYH
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32586056
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
Cools F; Wollaert B; Vervoort G; Verstraete S; Voet J; Hermans K; Heyse A; De Wolf A; Hollanders G; Boussy T; Anné W; Vercammen J; Faes D; Beutels M; Mairesse G; Purnode P; Blankoff I; Vandergoten P; Capiau L; Allu J; Bassand JP; Kayani G;
Acta Cardiol; 2019 Aug; 74(4):309-318. PubMed ID: 30369290
[No Abstract] [Full Text] [Related]
36. An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions.
Zhou J; Wang X; Yu J; Wu Y; Li X; Xie X; Zhang X; Cheng D; Yang B
Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):583-593. PubMed ID: 37057840
[TBL] [Abstract][Full Text] [Related]
37. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
38. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
Camm AJ; Accetta G; Ambrosio G; Atar D; Bassand JP; Berge E; Cools F; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Koretsune Y; Mantovani LG; Misselwitz F; Oh S; Turpie AG; Verheugt FW; Kakkar AK;
Heart; 2017 Feb; 103(4):307-314. PubMed ID: 27647168
[TBL] [Abstract][Full Text] [Related]
39. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF.
van der Wall SJ; Teutsch C; Dubner SJ; Diener HC; Halperin JL; Ma CS; Rothman KJ; Paquette M; Zint K; França LR; Lu S; Lip GYH; Huisman MV;
TH Open; 2021 Jan; 5(1):e35-e42. PubMed ID: 33564743
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
